Thymosin Alpha-1

Thymosin alpha-1 is a sequence-defined peptide comprising 28 amino-acid residues and an N-terminal acetyl group. Its reference sequence is Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, where the Ac prefix is part of the molecular identity rather than an optional formulation detail. The peptide is described as the N-terminal segment of prothymosin alpha, but prothymosin alpha itself is a larger precursor and not a synonym for the isolated 28-residue entity. The original biochemical isolation and sequence analysis established the chain length and terminal acetylation for the reference substance (Goldstein et al. 1977, biochemical isolation and sequence analysis, PMID 265536). That historical characterisation does not authenticate material from a current batch.

Two CAS numbers circulate for this molecular entry and should be disclosed rather than collapsed into one supposedly definitive number. CAS 62304-98-7 appears in the PubChem synonym set associated with the INN thymalfasin, while CAS 69521-94-4 is used by CAS Common Chemistry for the title Thymosin alpha-1. That INN designation serves here only as an identity and literature key. Neither CAS number alone establishes what is present in a received sample; the number on the released label and corresponding COA is the relevant documentary reference. Additional reference identifiers include molecular formula C129H215N33O55, an average mass of approximately 3108.3 g/mol for the free form, PubChem CID 16130571 and InChIKey NZVYCXVTEHPMHE-ZSUJOUNUSA-N.

The experimental literature describes thymosin alpha-1 as a subject of context-dependent immune modulation, not as a general immune stimulant. Modulation is the more accurate term because the cited studies measured particular signalling, differentiation and regulatory endpoints under defined conditions, sometimes with apparently different directional implications. They did not demonstrate a universal increase in immune activity. Much of this research concerns dendritic cells, Toll-like-receptor pathways and the balance between inflammatory and regulatory markers. Naming a pathway does not establish a single molecular target, and a marker change is not equivalent to an outcome beyond the experimental system in which it was recorded.

In a mouse study incorporating dendritic-cell experiments, Romani and colleagues reported maturation-related observations, IL-12 production and signalling associated with p38 MAPK, NF-kappaB, MyD88 and Toll-like receptors (Romani et al. 2004, animal model: mouse, PMID 14982877). These measurements belong to the fungal challenge, cellular preparation and mouse design used by the investigators. They support laboratory questions about linked signalling events but do not show that the same relationships occur across species, unrelated challenges or different protocols.

A separate in vitro study used murine bone-marrow-derived dendritic cells and examined differentiation and activation-marker expression. The reported IL-12 observations varied with experimental context, including the presence of TNF-alpha (Huang et al. 2004, in vitro: murine dendritic cells, PMID 15099531). This is direct cell-culture evidence, not an intact-animal experiment and not a human study. It is useful for separating cell-level observations from whole-system interpretation, while its species, culture conditions, exposure design and selected endpoints remain firm boundaries on any conclusion.

Tryptophan catabolism provides another example of why the literature should be read as modulation rather than simple stimulation. In a mouse model, investigators examined TLR9-related signalling, indoleamine 2,3-dioxygenase activity, tryptophan catabolism, IL-10 and regulatory T-cell generation under the study conditions (Romani et al. 2006, animal model: mouse, PMID 16741252). The reported dependencies on TLR9 and type-I interferon-receptor signalling are features of that experimental framework. They neither establish a universal mechanism nor justify transferring the observed network of endpoints to another species or model.

Bozza and colleagues examined plasmacytoid dendritic cells under an experimental murine viral condition and reported TLR9/MyD88-dependent sensing, IRF7 activation and interferon-related endpoints (Bozza et al. 2007, animal model: mouse, PMID 17804687). Again, the challenge model, sampling scheme and endpoint definitions are part of the evidence. The study does not convert a pathway association into a general property of every experimental system, and it provides no analytical information about a later manufactured sample.

Review literature occupies a different evidence layer. A mechanistic review organised prior findings concerning Toll-like receptors, dendritic cells and inflammatory and regulatory measurements (Romani et al. 2007, review, PMID 17495242). A later literature review addressed receptor-dependent mechanisms without its own sample analysis (King and Tuthill 2016, review, PMID 27450734). Reviews can map hypotheses, terminology and areas of convergence or disagreement. They do not generate a new experimental sample or independently reproduce every cited result.

Preparation chemistry sits in a layer of its own. Morozov and Khavinson reported the mild acid extraction of thymic peptides from calf thymus, the chromatographic isolation of a dipeptide fraction from that extract and the synthesis of defined dipeptides for comparison (Morozov and Khavinson 1997, isolation and characterisation, PMID 9637345). That work is cited here for one purpose only: it describes a thymus-derived extract as a mixture, which is what separates such a preparation from a single sequence-defined peptide. Its measurements were made on those preparations under the stated conditions and carry no analytical information about a later manufactured sample.

The evidence depth therefore has to remain explicit. Biochemical isolation and sequence analysis support the reference identity of the 28-residue N-acetylated peptide (Goldstein et al. 1977, PMID 265536), and a separate extraction and characterisation study describes the composition of thymus-derived preparations (Morozov and Khavinson 1997, PMID 9637345). Preclinical work includes a predominantly TP-1-exposed murine model whose NK-cell effect the abstract also reports for the distinct thymic factor Talpha-1, cultured murine dendritic cells and mouse models (Bistoni et al. 1984, PMID 6563944; Huang et al. 2004, PMID 15099531; Romani et al. 2004, PMID 14982877; Romani et al. 2006, PMID 16741252; Bozza et al. 2007, PMID 17804687). Clinical investigation designs are represented by a randomized multicentre study and a retrospective clinical cohort, without an endpoint or effect claim here (Wu et al. 2013, PMID 23327199; Liu et al. 2020, PMID 32442287). Reviews synthesize published work but do not provide new sample analysis (Low et al. 1979, PMID 394636; Romani et al. 2007, PMID 17495242; King and Tuthill 2016, PMID 27450734).

This corpus includes defined clinical investigation designs but does not establish clinical effectiveness, safety, a suitable procedure or guaranteed experimental outcomes. It does not support transfer from cultured murine cells to an intact organism, from mice to humans, or from one challenge model to another. It also does not prove a single receptor target or a uniform direction of response. Absence of a reported observation in these selected systems is not evidence of safety elsewhere. None of the publications supplies instructions for use, and none characterises the identity, composition, purity, content, storage condition or stability of the batch offered by a catalogue.

Literature identity and batch identity answer different questions. For a thymosin alpha 1 peptide sample, the product designation, SKU, label, batch code, specification and COA should refer to the same material and agree on the identifiers they report. The declared sequence must include the N-terminal acetylation if the material is assigned to this reference entity. The molecular form stated in the documentation must also be compatible with any reported analytical result. A discrepancy should be resolved before literature identity or an analytical value is attributed to the sample.

This documentary logic is normative, not a promise about a particular batch. A chromatographic result, if reported, applies only to the named sample, method and batch in its associated record; it cannot be generalised to other batches. Chromatographic purity does not by itself confirm the complete amino-acid sequence or N-terminal acetylation. Likewise, a reference formula or average mass does not establish salt form, hydration state, supplied content or presentation. Those characteristics require matching released documentation and appropriate analytical evidence. No purity percentage, quantity, supplied form or availability of a particular analytical package is claimed here.

Clear separation from similarly named materials keeps evidence and records from being misassigned. Thymalin is described as a thymus-derived polypeptide extract obtained by mild acid extraction, meaning a mixture rather than one uniquely sequence-defined species (Morozov and Khavinson 1997, isolation and characterisation, PMID 9637345). It is therefore not another name for thymosin alpha-1. Prothymosin alpha is the precursor from which the 28-residue N-terminal segment is described, not the finished sequence synonym. Beta-thymosins are a different peptide family with different sequences and literature. TB-500 is catalogued in relation to thymosin beta-4 material and is not interchangeable with this N-acetylated 28-residue molecule. Names, sequence records, specifications, COAs and study findings must remain substance-specific.

Thymosin alpha 1 is supplied exclusively as a subject for controlled laboratory research. The identity framework and cited publications are intended to support research cataloguing, literature review and model-qualified study planning. They do not replace local laboratory risk assessment, the applicable study protocol or batch-specific documentation. This material is not intended for human or veterinary use, and the page makes no therapeutic, diagnostic or outcome claim.